JNJ-87562761 Phase 2 Study Initiated for Relapsed/Refractory Multiple Myeloma
Janssen is conducting a study to establish the recommended phase 2 dose and assess safety of JNJ-87562761 in relapsed or refractory multiple myeloma patients.
Company
Pharmaceutical intelligence for JNJ-87562761 with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.